Literature DB >> 21160989

Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report.

Mumtaz A Niazi1, Ashaur Azhar, Kashif Tufail, Eyob L Feyssa, Stephen F Penny, Marlene McGregory, Victor Araya, Jorge A Ortiz.   

Abstract

The recommended therapy for chronic hepatitis C (CHC) infection is the combination of a Pegylated interferon and Ribavirin. Almost all such patients on combination therapy experience one or more adverse events during the course of treatment. Significant neurological side effects are rare. A few cases of Bell's Palsy, chronic inflammatory demyelinating polyneuropathy and even one case of acute demyelinating polyneuropathy with atypical features for Guillain-Barre syndrome (GBS) associated with Interferon therapy have been reported but no report of GBS with typical features has been published. We present a case report of typical GBS associated with Peginterferon alfa-2a and Ribavirin used for treatment of CHC infection.

Entities:  

Keywords:  Acute demyelinating polyneuropathy; Chronic hepatitis C; Guillain-Barre syndrome; Pegylated interferon; Polyneuropathy

Year:  2010        PMID: 21160989      PMCID: PMC2998962          DOI: 10.4254/wjh.v2.i4.162

Source DB:  PubMed          Journal:  World J Hepatol


  14 in total

1.  Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha.

Authors:  M N Meriggioli; J Rowin
Journal:  Muscle Nerve       Date:  2000-03       Impact factor: 3.217

2.  Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.

Authors:  K Ogawara; S Kuwabara; M Mori; T Hattori; M Koga; N Yuki
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

Review 3.  The burden of hepatitis C in the United States.

Authors:  W Ray Kim
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Early electrodiagnostic findings in Guillain-Barré syndrome.

Authors:  P H Gordon; A J Wilbourn
Journal:  Arch Neurol       Date:  2001-06

5.  Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States.

Authors:  S Deuffic-Burban; T Poynard; M S Sulkowski; J B Wong
Journal:  J Viral Hepat       Date:  2007-02       Impact factor: 3.728

6.  Criteria for diagnosis of Guillain-Barré syndrome.

Authors: 
Journal:  Ann Neurol       Date:  1978-06       Impact factor: 10.422

7.  Guillain-Barré syndrome following influenza vaccination.

Authors:  Penina Haber; Frank DeStefano; Fredrick J Angulo; John Iskander; Sean V Shadomy; Eric Weintraub; Robert T Chen
Journal:  JAMA       Date:  2004-11-24       Impact factor: 56.272

8.  Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R A C Hughes; E F M Wijdicks; R Barohn; E Benson; D R Cornblath; A F Hahn; J M Meythaler; R G Miller; J T Sladky; J C Stevens
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

Authors:  Serena S Spudich; Annelie C Nilsson; Nicole D Lollo; Teri J Liegler; Christos J Petropoulos; Steven G Deeks; Ellen E Paxinos; Richard W Price
Journal:  BMC Infect Dis       Date:  2005-11-02       Impact factor: 3.090

View more
  2 in total

1.  Reactivation of Chronic Hepatitis C as a Potential Trigger for Guillain-Barré Syndrome.

Authors:  Ogochukwu Molokwu; Brittany M Young; Manjit Singh; Krishe Menezes; Raza Mian
Journal:  Cureus       Date:  2019-07-26

2.  The introspection on the diagnosis and treatment process of a case of Guillain-Barré syndrome (GBS) attributed to systemic lupus erythematosus (SLE): A case report.

Authors:  Nan Zhang; Jie Cao; Meng Zhao; Li Sun
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.